Klaria Pharma Financials
| KLAR Stock | SEK 0.40 0.05 14.29% |
Klaria |
Please note, the imprecision that can be found in Klaria Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Klaria Pharma Holding. Check Klaria Pharma's Beneish M Score to see the likelihood of Klaria Pharma's management manipulating its earnings.
Klaria Pharma Stock Summary
Klaria Pharma competes with Kancera AB, Lidds AB, Cantargia, and Xintela AB. Klaria Pharma Holding AB develops treatment methods in the therapeutic fields of migraine and pain related to cancer worldwide. Klaria Pharma Holding AB was founded in 2014 and is based in Uppsala, Sweden. Klaria Pharma is traded on Stockholm Stock Exchange in Sweden.| Instrument | Sweden Stock View All |
| Exchange | Stockholm Exchange |
| ISIN | SE0007280326 |
| Business Address | Virdings All 2, |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Benchmark | Dow Jones Industrial |
| Website | www.klaria.com |
| Phone | 46 84 46 42 99 |
| Currency | SEK - Swedish Kronor |
You should never invest in Klaria Pharma without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Klaria Stock, because this is throwing your money away. Analyzing the key information contained in Klaria Pharma's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Klaria Pharma Key Financial Ratios
Klaria Pharma's financial ratios allow both analysts and investors to convert raw data from Klaria Pharma's financial statements into concise, actionable information that can be used to evaluate the performance of Klaria Pharma over time and compare it to other companies across industries.| Return On Equity | -0.88 | |||
| Return On Asset | -0.29 | |||
| Beta | 0.39 | |||
| Z Score | 22.8 |
Klaria Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Klaria Pharma's current stock value. Our valuation model uses many indicators to compare Klaria Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Klaria Pharma competition to find correlations between indicators driving Klaria Pharma's intrinsic value. More Info.Klaria Pharma Holding is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Klaria Pharma's earnings, one of the primary drivers of an investment's value.Klaria Pharma Holding Systematic Risk
Klaria Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Klaria Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Klaria Pharma Holding correlated with the market. If Beta is less than 0 Klaria Pharma generally moves in the opposite direction as compared to the market. If Klaria Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Klaria Pharma Holding is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Klaria Pharma is generally in the same direction as the market. If Beta > 1 Klaria Pharma moves generally in the same direction as, but more than the movement of the benchmark.
Klaria Pharma December 11, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Klaria Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Klaria Pharma Holding. We use our internally-developed statistical techniques to arrive at the intrinsic value of Klaria Pharma Holding based on widely used predictive technical indicators. In general, we focus on analyzing Klaria Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Klaria Pharma's daily price indicators and compare them against related drivers.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 42.33 | |||
| Value At Risk | (12.73) | |||
| Potential Upside | 9.43 |
Additional Tools for Klaria Stock Analysis
When running Klaria Pharma's price analysis, check to measure Klaria Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Klaria Pharma is operating at the current time. Most of Klaria Pharma's value examination focuses on studying past and present price action to predict the probability of Klaria Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Klaria Pharma's price. Additionally, you may evaluate how the addition of Klaria Pharma to your portfolios can decrease your overall portfolio volatility.